Food and Drug Safety Crises Prompt White House, Congressional Action - The FDA is poised to gain more authority and resources to ensure product quality. - BioPharm International

ADVERTISEMENT

Food and Drug Safety Crises Prompt White House, Congressional Action
The FDA is poised to gain more authority and resources to ensure product quality.


BioPharm International
Volume 22, Issue 4

MORE PROPOSALS

The focus on unsafe medical and food products is generating additional legislative proposals in the House and Senate. Rep. Rosa DeLauro (D-CN), chairman of the House Appropriations Committee that oversees the FDA's budget, recently re-introduced a bill to separate food regulation from medical product approvals by creating a separate Food Safety Administration that will provide needed attention to food safety. The FDA Food Safety Modernization Act, sponsored by Senate majority whip Richard Durbin (D-IL), proposes more targeted user fees for domestic and foreign food operators to support increased inspections, while also giving the FDA more power to monitor food quality and to recall noncompliant products.

The Durbin bill also addresses the need to protect food products from intentional contamination, an issue that reflects concerns about increased overseas production of pharmaceuticals and vaccines. Some members of Congress complain that the massive shift of pharmaceutical production to Asia and other regions not only exposes Americans to low quality and adulterated products, but may leave the US vulnerable to supply chain interruptions during a pandemic outbreak or other emergency.

Ironically, legislation that increases FDA inspections of foreign drug makers may re-open the door to drug importing. A group of leading senators is sponsoring a bill to allow nationwide re-importation of prescription drugs, claiming the program would save $50 billion over 10 years. All the imports would have to come from FDA-approved manufacturing plants in Canada, Europe, Australia, New Zealand, and Japan—a policy that assumes more frequent inspections and a viable pedigree system.

While Congress weighs these proposals, FDA is issuing guidance and launching initiatives that increase overseas inspections and provide greater assurance of drug quality. The FDA's "Beyond Our Borders" program is expanding into South America and India after opening offices in China a year ago and establishing a more formal presence in Brussels, Belgium. At the beginning of this year, the FDA also joined six federal agencies in issuing a government-wide policy to ensure "Good Importer Practices" for preventing and detecting hazards or contamination through a product's lifecycle. A new FDA voluntary secure supply chain pilot program will offer expedited entry to drug manufacturers able to demonstrate control over their supply chain from time of manufacture through entry into the US. The two-year initiative will start with up to five products from 100 manufacturers and aims to identify strategies for preventing import of contaminated or counterfeit drugs. And the FDA is supporting supply chain security by establishing a standardized numerical identifier for drugs and biologics, as required by the FDA Amendments Act of 2007. A guidance document issued in January (2009) advises manufacturers to use a product's national drug code plus a unique eight-digit serial number for identifying drug packages.

A common thread in FDA and Congressional initiatives is that manufacturers are ultimately responsible for the quality and safety of their products, and that the FDA will never be able to detect every product failure. Increased foreign sourcing of ingredients creates ever more complex supply chains and new challenges in protecting against product contamination, diversion, and counterfeiting. Manufacturers emphasize the need for a universal drug pedigree system that can document product sourcing, and additional legislation may further support harmonization of practices and policies for ensuring product quality through the supply chain.

Jill Wechsler is BioPharm International's Washington editor, Chevy Chase, MD, 301.656.4634,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here